Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Nov;50(Suppl 4):854–861. doi: 10.1136/ard.50.suppl_4.854

Clinical aspects of systemic sclerosis (scleroderma).

R M Silver 1
PMCID: PMC1033320  PMID: 1750797

Full text

PDF
854

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberer E., Stanek G., Ertl M., Neumann R. Evidence for spirochetal origin of circumscribed scleroderma (morphea). Acta Derm Venereol. 1987;67(3):225–231. [PubMed] [Google Scholar]
  2. Alexander E. L., Firestein G. S., Weiss J. L., Heuser R. R., Leitl G., Wagner H. N., Jr, Brinker J. A., Ciuffo A. A., Becker L. C. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986 Nov;105(5):661–668. doi: 10.7326/0003-4819-105-5-661. [DOI] [PubMed] [Google Scholar]
  3. Bernstein R. M., Pereira R. S., Holden A. J., Black C. M., Howard A., Ansell B. M. Autoantibodies in childhood scleroderma. Ann Rheum Dis. 1985 Aug;44(8):503–506. doi: 10.1136/ard.44.8.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Black C. M., Welsh K. I., Maddison P. J., Jayson M. I., Bernstein R. M. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol. 1984 Nov;23(4):267–271. doi: 10.1093/rheumatology/23.4.267. [DOI] [PubMed] [Google Scholar]
  5. Black C. M., Welsh K. I., Walker A. E., Bernstein R. M., Catoggio L. J., McGregor A. R., Jones J. K. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet. 1983 Jan 1;1(8314-5):53–55. doi: 10.1016/s0140-6736(83)91578-7. [DOI] [PubMed] [Google Scholar]
  6. Cannon P. J., Hassar M., Case D. B., Casarella W. J., Sommers S. C., LeRoy E. C. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 1974 Jan;53(1):1–46. doi: 10.1097/00005792-197401000-00001. [DOI] [PubMed] [Google Scholar]
  7. Chen Z. Y., Silver R. M., Ainsworth S. K., Dobson R. L., Rust P., Maricq H. R. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med. 1984 Nov;77(5):812–822. doi: 10.1016/0002-9343(84)90517-5. [DOI] [PubMed] [Google Scholar]
  8. Douvas A. Does Sc1-70 modulate collagen production in systemic sclerosis? Lancet. 1988 Aug 27;2(8609):475–477. doi: 10.1016/s0140-6736(88)90122-5. [DOI] [PubMed] [Google Scholar]
  9. Duncan M. R., Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest. 1987 May;79(5):1318–1324. doi: 10.1172/JCI112956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Earnshaw W., Bordwell B., Marino C., Rothfield N. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest. 1986 Feb;77(2):426–430. doi: 10.1172/JCI112320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ellis W. W., Baer A. N., Robertson R. M., Pincus T., Kronenberg M. W. Left ventricular dysfunction induced by cold exposure in patients with systemic sclerosis. Am J Med. 1986 Mar;80(3):385–392. doi: 10.1016/0002-9343(86)90711-4. [DOI] [PubMed] [Google Scholar]
  12. Falanga V., Medsger T. A., Jr Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol. 1987 Oct;17(4):648–656. doi: 10.1016/s0190-9622(87)70251-5. [DOI] [PubMed] [Google Scholar]
  13. Falanga V., Medsger T. A., Jr, Reichlin M., Rodnan G. P. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986 Jun;104(6):849–857. doi: 10.7326/0003-4819-104-6-849. [DOI] [PubMed] [Google Scholar]
  14. Fitzgerald O., Hess E. V., O'Connor G. T., Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med. 1988 Apr;84(4):718–726. doi: 10.1016/0002-9343(88)90109-x. [DOI] [PubMed] [Google Scholar]
  15. Furst D. E., Davis J. A., Clements P. J., Chopra S. K., Theofilopoulos A. N., Chia D. Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum. 1981 Nov;24(11):1403–1408. doi: 10.1002/art.1780241111. [DOI] [PubMed] [Google Scholar]
  16. Garioch J. J., Rashid A., Thomson J., Seywright M. The relevance of elevated Borrelia burgdorferi titres in localized scleroderma. Clin Exp Dermatol. 1989 Nov;14(6):439–441. doi: 10.1111/j.1365-2230.1989.tb02607.x. [DOI] [PubMed] [Google Scholar]
  17. Grisanti M. W., Moore T. L., Osborn T. G., Haber P. L. Eosinophilic fasciitis in children. Semin Arthritis Rheum. 1989 Dec;19(3):151–157. doi: 10.1016/0049-0172(89)90027-9. [DOI] [PubMed] [Google Scholar]
  18. Harper F. E., Maricq H. R., Turner R. E., Lidman R. W., Leroy E. C. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med. 1982 Jun;72(6):883–888. doi: 10.1016/0002-9343(82)90846-4. [DOI] [PubMed] [Google Scholar]
  19. Harrison N. K., Glanville A. R., Strickland B., Haslam P. L., Corrin B., Addis B. J., Lawrence R., Millar A. B., Black C. M., Turner-Warwick M. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med. 1989 Sep;83(5):403–414. doi: 10.1016/s0954-6111(89)80072-1. [DOI] [PubMed] [Google Scholar]
  20. Hawkins R. A., Claman H. N., Clark R. A., Steigerwald J. C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med. 1985 Feb;102(2):182–186. doi: 10.7326/0003-4819-102-2-182. [DOI] [PubMed] [Google Scholar]
  21. Helfrich D. J., Banner B., Steen V. D., Medsger T. A., Jr Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989 Sep;32(9):1128–1134. doi: 10.1002/anr.1780320911. [DOI] [PubMed] [Google Scholar]
  22. Hendel L., Worning H. Exocrine pancreatic function in patients with progressive systemic sclerosis. Scand J Gastroenterol. 1989 May;24(4):461–466. doi: 10.3109/00365528909093075. [DOI] [PubMed] [Google Scholar]
  23. Jones B., Trevillian P., Lake N. Continuous ambulatory peritoneal dialysis in scleroderma. Nephron. 1990;54(1):107–108. doi: 10.1159/000185826. [DOI] [PubMed] [Google Scholar]
  24. Kahaleh M. B., Osborn I., LeRoy E. C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981 Apr;94(4 Pt 1):482–484. doi: 10.7326/0003-4819-94-4-482. [DOI] [PubMed] [Google Scholar]
  25. Kahaleh M. B., Smith E. A., Soma Y., LeRoy E. C. Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and function. Clin Immunol Immunopathol. 1988 Nov;49(2):261–272. doi: 10.1016/0090-1229(88)90116-x. [DOI] [PubMed] [Google Scholar]
  26. Kahan A., Devaux J. Y., Amor B., Menkès C. J., Weber S., Nitenberg A., Venot A., Guérin F., Degeorges M., Roucayrol J. C. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986 May 29;314(22):1397–1402. doi: 10.1056/NEJM198605293142201. [DOI] [PubMed] [Google Scholar]
  27. Kallenberg C. G., Wouda A. A., Hoet M. H., van Venrooij W. J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988 Aug;47(8):634–641. doi: 10.1136/ard.47.8.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kikuchi K., Takehara K., Ishibashi Y. Antinuclear antibodies in localized scleroderma: unique staining in chromosome spreads. J Am Acad Dermatol. 1989 Dec;21(6):1301–1303. doi: 10.1016/s0190-9622(89)80310-x. [DOI] [PubMed] [Google Scholar]
  29. Kinsella M. B., Smith E. A., Miller K. S., LeRoy E. C., Silver R. M. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum. 1989 May;32(5):577–583. doi: 10.1002/anr.1780320511. [DOI] [PubMed] [Google Scholar]
  30. Kähäri V. M., Multimäki P., Vuorio E. Elevated pro alpha 2(I) collagen mRNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding gene. FEBS Lett. 1987 May 11;215(2):331–334. doi: 10.1016/0014-5793(87)80172-2. [DOI] [PubMed] [Google Scholar]
  31. König G., Luderschmidt C., Hammer C., Adelmann-Grill B. C., Braun-Falco O., Fruhmann G. Lung involvement in scleroderma. Chest. 1984 Mar;85(3):318–324. doi: 10.1378/chest.85.3.318. [DOI] [PubMed] [Google Scholar]
  32. LeRoy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed] [Google Scholar]
  33. Lecerf V., Bagot M., Revuz J., Touraine R., Dournon E. Borrelia burgdorferi and localized scleroderma. Arch Dermatol. 1989 Feb;125(2):297–297. doi: 10.1001/archderm.1989.01670140149031. [DOI] [PubMed] [Google Scholar]
  34. Leof E. B., Proper J. A., Goustin A. S., Shipley G. D., DiCorleto P. E., Moses H. L. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2453–2457. doi: 10.1073/pnas.83.8.2453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Leroy E. C. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med. 1972 Jun 1;135(6):1351–1362. doi: 10.1084/jem.135.6.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Leroy E. C., Smith E. A., Kahaleh M. B., Trojanowska M., Silver R. M. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum. 1989 Jul;32(7):817–825. [PubMed] [Google Scholar]
  37. Lomeo R. M., Cornella R. J., Schabel S. I., Silver R. M. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med. 1989 Nov;87(5):525–527. doi: 10.1016/s0002-9343(89)80608-4. [DOI] [PubMed] [Google Scholar]
  38. Maricq H. R., Weinrich M. C. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol. 1988 Mar;15(3):454–459. [PubMed] [Google Scholar]
  39. Maricq H. R., Weinrich M. C., Keil J. E., LeRoy E. C. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis. 1986;39(6):423–427. doi: 10.1016/0021-9681(86)90109-8. [DOI] [PubMed] [Google Scholar]
  40. Masi A. T. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol. 1988 Jun;15(6):894–898. [PubMed] [Google Scholar]
  41. McGregor A. R., Watson A., Yunis E., Pandey J. P., Takehara K., Tidwell J. T., Ruggieri A., Silver R. M., LeRoy E. C., Maricq H. R. Familial clustering of scleroderma spectrum disease. Am J Med. 1988 Jun;84(6):1023–1032. doi: 10.1016/0002-9343(88)90307-5. [DOI] [PubMed] [Google Scholar]
  42. Owens G. R., Paradis I. L., Gryzan S., Medsger T. A., Jr, Follansbee W. P., Klein H. A., Dauber J. H. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. J Lab Clin Med. 1986 Mar;107(3):253–260. [PubMed] [Google Scholar]
  43. Priollet P., Vayssairat M., Housset E. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases. Am J Med. 1987 Sep;83(3):494–498. doi: 10.1016/0002-9343(87)90760-1. [DOI] [PubMed] [Google Scholar]
  44. Reimer G., Rose K. M., Scheer U., Tan E. M. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest. 1987 Jan;79(1):65–72. doi: 10.1172/JCI112809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rittner G., Schwanitz G., Baur M. P., Black C. M., Welsh K. I., Kühnl P., Rittner C. Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet. 1988 Dec;81(1):64–70. doi: 10.1007/BF00283732. [DOI] [PubMed] [Google Scholar]
  46. Roberts A. B., Sporn M. B., Assoian R. K., Smith J. M., Roche N. S., Wakefield L. M., Heine U. I., Liotta L. A., Falanga V., Kehrl J. H. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. doi: 10.1073/pnas.83.12.4167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rocco V. K., Hurd E. R. Scleroderma and scleroderma-like disorders. Semin Arthritis Rheum. 1986 Aug;16(1):22–69. doi: 10.1016/0049-0172(86)90040-5. [DOI] [PubMed] [Google Scholar]
  48. Rossi G. A., Bitterman P. B., Rennard S. I., Ferrans V. J., Crystal R. G. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis. 1985 Apr;131(4):612–617. doi: 10.1164/arrd.1985.131.4.612. [DOI] [PubMed] [Google Scholar]
  49. Rossi P., Karsenty G., Roberts A. B., Roche N. S., Sporn M. B., de Crombrugghe B. A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Cell. 1988 Feb 12;52(3):405–414. doi: 10.1016/s0092-8674(88)80033-3. [DOI] [PubMed] [Google Scholar]
  50. Sandborg C. I., Berman M. A., Andrews B. S., Mirick G. R., Friou G. J. Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma. Clin Exp Immunol. 1986 Nov;66(2):312–319. [PMC free article] [PubMed] [Google Scholar]
  51. Sato N., Goto T., Haranaka K., Satomi N., Nariuchi H., Mano-Hirano Y., Sawasaki Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst. 1986 Jun;76(6):1113–1121. [PubMed] [Google Scholar]
  52. Senaldi G., Lupoli S., Vergani D., Black C. M. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum. 1989 Oct;32(10):1262–1267. doi: 10.1002/anr.1780321011. [DOI] [PubMed] [Google Scholar]
  53. Shero J. H., Bordwell B., Rothfield N. F., Earnshaw W. C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science. 1986 Feb 14;231(4739):737–740. doi: 10.1126/science.3003910. [DOI] [PubMed] [Google Scholar]
  54. Silver R. M., Heyes M. P., Maize J. C., Quearry B., Vionnet-Fuasset M., Sternberg E. M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29;322(13):874–881. doi: 10.1056/NEJM199003293221302. [DOI] [PubMed] [Google Scholar]
  55. Silver R. M., Metcalf J. F., LeRoy E. C. Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum. 1986 Apr;29(4):525–531. doi: 10.1002/art.1780290410. [DOI] [PubMed] [Google Scholar]
  56. Silver R. M., Metcalf J. F., Stanley J. H., LeRoy E. C. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984 Nov;27(11):1254–1262. doi: 10.1002/art.1780271107. [DOI] [PubMed] [Google Scholar]
  57. Silver R. M., Miller K. S., Kinsella M. B., Smith E. A., Schabel S. I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990 May;88(5):470–476. doi: 10.1016/0002-9343(90)90425-d. [DOI] [PubMed] [Google Scholar]
  58. Steen V. D., Medsger T. A., Jr, Osial T. A., Jr, Ziegler G. L., Shapiro A. P., Rodnan G. P. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984 May;76(5):779–786. doi: 10.1016/0002-9343(84)90986-0. [DOI] [PubMed] [Google Scholar]
  59. Sternberg E. M., Van Woert M. H., Young S. N., Magnussen I., Baker H., Gauthier S., Osterland C. K. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782–787. doi: 10.1056/NEJM198010023031403. [DOI] [PubMed] [Google Scholar]
  60. Takehara K., LeRoy E. C., Grotendorst G. R. TGF-beta inhibition of endothelial cell proliferation: alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression. Cell. 1987 May 8;49(3):415–422. doi: 10.1016/0092-8674(87)90294-7. [DOI] [PubMed] [Google Scholar]
  61. Takehara K., Moroi Y., Ishibashi Y. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol. 1985 Jan;112(1):23–33. doi: 10.1111/j.1365-2133.1985.tb02287.x. [DOI] [PubMed] [Google Scholar]
  62. Tazelaar H. D., Myers J. L., Drage C. W., King T. E., Jr, Aguayo S., Colby T. V. Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest. 1990 May;97(5):1032–1036. doi: 10.1378/chest.97.5.1032. [DOI] [PubMed] [Google Scholar]
  63. Waeber B., Schaller M. D., Wauters J. P., Brunner H. R. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril. Klin Wochenschr. 1984 Aug 1;62(15):728–730. doi: 10.1007/BF01725706. [DOI] [PubMed] [Google Scholar]
  64. Walker M. A., Harley R. A., LeRoy E. C. Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. J Rheumatol. 1987 Apr;14(2):299–301. [PubMed] [Google Scholar]
  65. Walker M., Harley R., LeRoy E. C. Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol. 1990 Jan;17(1):57–59. [PubMed] [Google Scholar]
  66. Wallaert B., Hatron P. Y., Grosbois J. M., Tonnel A. B., Devulder B., Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis. 1986 Apr;133(4):574–580. doi: 10.1164/arrd.1986.133.4.574. [DOI] [PubMed] [Google Scholar]
  67. Wollersheim H., Thien T., Hoet M. H., Van Venrooy W. J. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest. 1989 Dec;19(6):535–541. doi: 10.1111/j.1365-2362.1989.tb00271.x. [DOI] [PubMed] [Google Scholar]
  68. Zaninotto G., Peserico A., Costantini M., Salvador L., Rondinone R., Roveran A., Piasentin G., Glorioso S., Merigliano S., Ancona E. Oesophageal motility and lower oesophageal sphincter competence in progressive systemic sclerosis and localized scleroderma. Scand J Gastroenterol. 1989 Jan;24(1):95–102. doi: 10.3109/00365528909092245. [DOI] [PubMed] [Google Scholar]
  69. al-Sabbagh M. R., Steen V. D., Zee B. C., Nalesnik M., Trostle D. C., Bedetti C. D., Medsger T. A., Jr Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol. 1989 Aug;16(8):1038–1042. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES